Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Acute Respiratory Distress Syndrome (ARDS) Clinical Trials

A listing of Acute Respiratory Distress Syndrome (ARDS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (88) clinical trials

For newborn infants born with a deficiency in lung surfactant because of prematurity or other causes of delayed lung maturation, lung surfactant replacement therapy is life saving. The objective of this trial is to demonstrate that there is a group of patients who can benefit from surfactant replacement therapy with lower ...

Phase N/A

Patients are needed to participate in a clinical research study evaluating inhaled molgramostim (rhGM-CSF), inhaled placebo for the treatment of ADULT RESPIRATORY DISTRESS SYNDROME

This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with pneumonia associated acute respiratory distress syndrome (ARDS). A third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. The patients will ...


A Phase 1/2 Study to Assess MultiStem Therapy in Acute Respiratory Distress Syndrome

A study to examine the safety (and potential efficacy) of the adult stem cell investigational product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS). The primary hypothesis is that MultiStem will be safe in ARDS patients.


Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

This is a Phase III clinical study to investigate the efficacy and safety of FP-1201-lyo (recombinant human interferon [IFN] beta-1a) compared to placebo in patients diagnosed with moderate or severe acute respiratory distress syndrome (ARDS). Primary objective is to demonstrate the efficacy of FP-1201-lyo in improving the clinical course and ...


Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

ARDS is defined by acute hypoxemia, respiratory failure and the presence of bilateral lung infiltrates. ARDS is a syndrome of inflammation and increased permeability that may coexist with left atrial or pulmonary capillary hypertension. Several recent trials in ARDS/ALI (Acute Lung Injury) have generated interest in the use of Prostacyclin ...


Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with acute lung injury,open label, controlled prospective study. Every patient will maintain their standard treatment of acute lung injury, with maximum tolerated dosage without side effects. The day of infusion will be considered day ...


Observational Cohort Study of Distribution of Ventilation in Pediatrics Requiring Mechanical Ventilation by Electrical Impedance Tomography

Specific Aims/Objectives Specific Aim 1: To determine regional compliance and distribution of ventilation in a cohort of children requiring mechanical ventilation. Hypothesis - Abnormal distribution of ventilation will be discovered in all patients. Specific Aim 2: To determine changes in regional distribution of ventilation over the course of mechanical ventilation ...

Phase N/A

Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS

Current best practices for management of severe ARDS include lung protective ventilation and nursing in the prone position. However, the best lung protective strategy is not currently established and using smaller ventilation volumes than standard lung protective ventilation suggest lung recovery is improved. Application of smaller ventilation volumes requires extracorporeal ...

Phase N/A

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

PROTOCOL OUTLINE: This is a dose escalation study. Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours. Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until the maximum tolerated dose is determined. Patients are followed for 30 days.


Molecular Epidemiology of ARDS

BACKGROUND The acute respiratory distress syndrome (ARDS) remains a major cause of morbidity and mortality around the world. In the United States alone there are 150,000 cases per year. Although there have been significant scientific advances in understanding the clinical and pathophysical aspects of the syndrome, there is as yet ...

Phase N/A